NZ523960A - Compounds that inhibit de novo lipogenesis in mammals used for treatment and/or prophylaxis of obesity - Google Patents
Compounds that inhibit de novo lipogenesis in mammals used for treatment and/or prophylaxis of obesityInfo
- Publication number
- NZ523960A NZ523960A NZ52396001A NZ52396001A NZ523960A NZ 523960 A NZ523960 A NZ 523960A NZ 52396001 A NZ52396001 A NZ 52396001A NZ 52396001 A NZ52396001 A NZ 52396001A NZ 523960 A NZ523960 A NZ 523960A
- Authority
- NZ
- New Zealand
- Prior art keywords
- prophylaxis
- obesity
- inhibit
- compounds
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
- C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10035227A DE10035227A1 (en) | 2000-07-20 | 2000-07-20 | Selection and use of lipogenesis inhibitors for the treatment and prevention of obesity |
| PCT/EP2001/008051 WO2002007821A1 (en) | 2000-07-20 | 2001-07-12 | Method for locating compounds which are suitable for the treatment and/or prophylaxis of obesity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ523960A true NZ523960A (en) | 2004-12-24 |
Family
ID=7649538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ52396001A NZ523960A (en) | 2000-07-20 | 2001-07-12 | Compounds that inhibit de novo lipogenesis in mammals used for treatment and/or prophylaxis of obesity |
Country Status (27)
| Country | Link |
|---|---|
| EP (1) | EP1307262B1 (en) |
| JP (1) | JP2004504053A (en) |
| KR (1) | KR100818827B1 (en) |
| CN (1) | CN1443085B (en) |
| AR (1) | AR028730A1 (en) |
| AT (1) | ATE278441T1 (en) |
| AU (2) | AU2001277534B9 (en) |
| BR (1) | BR0112547A (en) |
| CA (1) | CA2416647A1 (en) |
| CZ (1) | CZ2003156A3 (en) |
| DE (2) | DE10035227A1 (en) |
| DZ (1) | DZ3393A1 (en) |
| ES (1) | ES2230346T3 (en) |
| HK (1) | HK1057499A1 (en) |
| HU (1) | HUP0302309A3 (en) |
| IL (2) | IL153971A0 (en) |
| MX (1) | MXPA02012907A (en) |
| NO (1) | NO20030233L (en) |
| NZ (1) | NZ523960A (en) |
| PL (1) | PL201165B1 (en) |
| PT (1) | PT1307262E (en) |
| RU (1) | RU2268721C2 (en) |
| SK (1) | SK287607B6 (en) |
| TR (1) | TR200402670T4 (en) |
| TW (1) | TWI274157B (en) |
| UA (1) | UA74588C2 (en) |
| WO (1) | WO2002007821A1 (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1997370B (en) | 2004-05-19 | 2011-06-01 | 索尔瓦药物有限公司 | Use of n-sulfamoyl-n'-arylpiperazines in preparing medicine for the prophylaxis or treatment of obesity and related conditions |
| MY147767A (en) | 2004-06-16 | 2013-01-31 | Janssen Pharmaceutica Nv | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
| KR20080012360A (en) | 2005-05-20 | 2008-02-11 | 얀센 파마슈티카 엔.브이. | Process for preparation of sulfamide derivatives |
| AR057570A1 (en) | 2005-11-14 | 2007-12-05 | Solvay Pharm Gmbh | DERIVATIVES OF N-SULFAMOIL-N'-BENZOPIRANOPIPERIDINAS ESPIROCONDENSADAS, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, A PROCEDURE FOR THEIR PREPARATION AND ITS USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF DISEASES MEDIATED BY ISOIDAS IIB |
| US8492431B2 (en) * | 2005-12-19 | 2013-07-23 | Janssen Pharmaceutica, N.V. | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity |
| US8937096B2 (en) | 2005-12-19 | 2015-01-20 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder |
| US8497298B2 (en) | 2005-12-19 | 2013-07-30 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels |
| US8691867B2 (en) | 2005-12-19 | 2014-04-08 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction |
| US8716231B2 (en) | 2005-12-19 | 2014-05-06 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain |
| TW200812573A (en) | 2006-05-19 | 2008-03-16 | Janssen Pharmaceutica Nv | Co-therapy for the treatment of epilepsy and related disorders |
| NO2106260T3 (en) | 2007-01-25 | 2018-05-05 | ||
| US8809385B2 (en) | 2008-06-23 | 2014-08-19 | Janssen Pharmaceutica Nv | Crystalline form of (2S)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide |
| US8815939B2 (en) | 2008-07-22 | 2014-08-26 | Janssen Pharmaceutica Nv | Substituted sulfamide derivatives |
| KR20150023405A (en) * | 2012-05-24 | 2015-03-05 | 베바 파마슈티칼스 엘티디 | A Method of Improving Liver Function |
| CN106770611B (en) * | 2016-12-22 | 2019-01-29 | 广西师范大学 | A method of entering mitochondria for cell in-situ detection small molecule compound |
| RU2771430C1 (en) * | 2021-09-21 | 2022-05-04 | Федеральное государственное бюджетное научное учреждение "Научный центр неврологии" (ФГБНУ НЦН) | Method for the quantitative determination of anticonvulsants in the blood plasma of patients with epilepsy |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4552897A (en) * | 1983-02-01 | 1985-11-12 | American Cyanamid Company | Salts of 1-(aminodihalophenyl)-2-aminoethanols and antilipogenic compositions prepared therefrom |
| US6288095B1 (en) * | 1987-09-04 | 2001-09-11 | Beecham Group P.L.C. | Compounds |
| US5126324A (en) * | 1990-06-07 | 1992-06-30 | Genentech, Inc. | Method of enhancing growth in patients using combination therapy |
| JPH08502969A (en) * | 1992-10-29 | 1996-04-02 | ジェネンテク，インコーポレイテッド | How to prevent or treat obesity |
| AU693478B2 (en) * | 1994-11-10 | 1998-07-02 | Metabolic Pharmaceuticals Limited | Treatment of obesity |
| CA2258893C (en) * | 1996-06-28 | 2005-06-14 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant sulfamate derivatives useful in treating obesity |
| US20030100594A1 (en) * | 2001-08-10 | 2003-05-29 | Pharmacia Corporation | Carbonic anhydrase inhibitor |
-
2000
- 2000-07-20 DE DE10035227A patent/DE10035227A1/en not_active Withdrawn
-
2001
- 2001-06-15 AR ARP010102883A patent/AR028730A1/en unknown
- 2001-07-12 AU AU2001277534A patent/AU2001277534B9/en not_active Ceased
- 2001-07-12 IL IL15397101A patent/IL153971A0/en unknown
- 2001-07-12 AT AT01955345T patent/ATE278441T1/en active
- 2001-07-12 TR TR2004/02670T patent/TR200402670T4/en unknown
- 2001-07-12 NZ NZ52396001A patent/NZ523960A/en not_active IP Right Cessation
- 2001-07-12 JP JP2002513551A patent/JP2004504053A/en active Pending
- 2001-07-12 EP EP01955345A patent/EP1307262B1/en not_active Expired - Lifetime
- 2001-07-12 PL PL363518A patent/PL201165B1/en not_active IP Right Cessation
- 2001-07-12 PT PT01955345T patent/PT1307262E/en unknown
- 2001-07-12 ES ES01955345T patent/ES2230346T3/en not_active Expired - Lifetime
- 2001-07-12 CZ CZ2003156A patent/CZ2003156A3/en unknown
- 2001-07-12 CA CA002416647A patent/CA2416647A1/en not_active Abandoned
- 2001-07-12 DZ DZ013393A patent/DZ3393A1/en active
- 2001-07-12 SK SK61-2003A patent/SK287607B6/en not_active IP Right Cessation
- 2001-07-12 BR BR0112547-8A patent/BR0112547A/en not_active Application Discontinuation
- 2001-07-12 DE DE50104023T patent/DE50104023D1/en not_active Expired - Lifetime
- 2001-07-12 HU HU0302309A patent/HUP0302309A3/en unknown
- 2001-07-12 RU RU2003104803/14A patent/RU2268721C2/en not_active IP Right Cessation
- 2001-07-12 MX MXPA02012907A patent/MXPA02012907A/en active IP Right Grant
- 2001-07-12 CN CN018129730A patent/CN1443085B/en not_active Expired - Fee Related
- 2001-07-12 WO PCT/EP2001/008051 patent/WO2002007821A1/en active IP Right Grant
- 2001-07-12 KR KR1020037000620A patent/KR100818827B1/en not_active IP Right Cessation
- 2001-07-12 AU AU7753401A patent/AU7753401A/en active Pending
- 2001-07-16 TW TW090117382A patent/TWI274157B/en not_active IP Right Cessation
- 2001-12-07 UA UA2003021453A patent/UA74588C2/en unknown
-
2003
- 2003-01-15 IL IL153971A patent/IL153971A/en not_active IP Right Cessation
- 2003-01-17 NO NO20030233A patent/NO20030233L/en unknown
-
2004
- 2004-01-15 HK HK04100307.4A patent/HK1057499A1/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ523960A (en) | Compounds that inhibit de novo lipogenesis in mammals used for treatment and/or prophylaxis of obesity | |
| HK1061669A1 (en) | Processes and compositions for water treatment | |
| HK1062518A1 (en) | Materials and methods for the treatment or prevention of obesity | |
| HK1094909A1 (en) | Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis il-18 | |
| EG22394A (en) | Acidic antimicrobial compositions for treating food and food contact surfaces and methods of use thereof | |
| AU2001247331A1 (en) | Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders | |
| AU2001239052A1 (en) | Compositions for prevention and treatment of dementia | |
| AU6008101A (en) | Benzophenones as inhibitors of il-1beta and tnf-alpha | |
| AU2001277534A1 (en) | Method for locating compounds which are suitable for the treatment and/or prophylaxis of obesity | |
| HUP0204048A3 (en) | Use of desloratadine for treating allergic and inflammatory conditions | |
| GB0115707D0 (en) | Treatment and prevention of lipodermatosclerosis | |
| HUP0302738A3 (en) | Use of sarp-1 for the treatment and/or prevention of scleroderma | |
| EP1280546A4 (en) | Method and composition for the treatment of angiogenesis | |
| EP1109749A4 (en) | In situ treatment for contaminated surface waters and products therefor | |
| EP1305017A4 (en) | Methods and compositions for the prevention and treatment of syndrome x | |
| HK1021314A1 (en) | Formulation for the treatment and/or prophylaxis of dementia | |
| HU0000207D0 (en) | Composition and method for treating sclerotinia infection | |
| GB0016445D0 (en) | A method of treatment and/or prophylaxis | |
| GB9808562D0 (en) | Treatment of stroke and other ischaemic conditions | |
| IL150525A0 (en) | 2-carboxamide-benzimidazoles useful in the treatment and prevention of isochemic reperfusion injury | |
| SI1307262T1 (en) | Method for locating compounds which are suitable for the treatment and/or prophylaxis of obesity | |
| GB9719596D0 (en) | Treatment and prophylaxis of infarction | |
| GB9715198D0 (en) | Treatment and prophylaxis of infarction | |
| EP1225912A4 (en) | A method of prophylaxis and treatment | |
| GB9928681D0 (en) | Method and composition for treatment or prophylaxis of diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| LAPS | Patent lapsed |